Lanean...

Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?

CT-P13, the world’s first biosimilar monoclonal antibody to infliximab, was approved for marketing in South Korea for all the six indications of infliximab, which Europe may follow, although the product was tested only in rheumatoid arthritis (RA) with a limited pharmacokinetic comparison in ankylos...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile nagusia: Lee, Howard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2013
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3889539/
https://ncbi.nlm.nih.gov/pubmed/24114449
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1208/s12248-013-9534-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!